Trial · NCT01263132
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Neuropathic Pain Score at Visit 3 (Week 1) | Gabapentin | 51.00 | Standard Deviation 17.39 | Units on a Scale | |
| Mean Neuropathic Pain Score at Visit 3 (Week 1) | MF0434 + Gabapentin | 50.70 | Standard Deviation 16.67 | Units on a Scale | |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | Gabapentin | Baseline (Visit 2): General SF-36 QoL Index | 53.044 | Standard Deviation 22.409 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | MF0434 + Gabapentin | Baseline (Visit 2): General SF-36 QoL Index | 56.507 | Standard Deviation 19.523 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | Gabapentin | Week 1 (Visit 3): General SF-36 QoL Index | 65.779 | Standard Deviation 20.882 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | MF0434 + Gabapentin | Week 1 (Visit 3): General SF-36 QoL Index | 65.610 | Standard Deviation 18.599 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | Gabapentin | Week 2 (Visit 4): General SF-36 QoL Index | 69.531 | Standard Deviation 18.987 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | MF0434 + Gabapentin | Week 2 (Visit 4): General SF-36 QoL Index | 74.370 | Standard Deviation 15.595 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | Gabapentin | Week 3 (Visit 5): General SF-36 QoL Index | 73.058 | Standard Deviation 18.102 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | MF0434 + Gabapentin | Week 3 (Visit 5): General SF-36 QoL Index | 78.075 | Standard Deviation 15.819 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | Gabapentin | Week 4 (Visit 6): General SF-36 QoL Index | 78.869 | Standard Deviation 17.010 | Units on a Scale |
| Quality of Life Survey Assessed Using Short Form 36 (SF-36) Questionnaire | MF0434 + Gabapentin | Week 4 (Visit 6): General SF-36 QoL Index | 82.331 | Standard Deviation 15.793 | Units on a Scale |
| Mean Neuropathic Pain Score at Visit 4 (Week 2) | Gabapentin | 41.24 | Standard Deviation 16.21 | Units on a Scale | |
| Mean Neuropathic Pain Score at Visit 4 (Week 2) | MF0434 + Gabapentin | 36.94 | Standard Deviation 15.05 | Units on a Scale | |
| Mean Neuropathic Pain Score at Visit 5 (Week 3) | Gabapentin | 33.74 | Standard Deviation 19.54 | Units on a Scale | |
| Mean Neuropathic Pain Score at Visit 5 (Week 3) | MF0434 + Gabapentin | 24.86 | Standard Deviation 13.52 | Units on a Scale | |
| Mean Neuropathic Pain Score at Visit 6 (Week 4) | Gabapentin | 22.08 | Standard Deviation 18.54 | Units on a Scale | |
| Mean Neuropathic Pain Score at Visit 6 (Week 4) | MF0434 + Gabapentin | 17.29 | Standard Deviation 15.53 | Units on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263132/results